Compare GMAB & COHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMAB | COHR |
|---|---|---|
| Founded | 1999 | 1971 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1B | 21.9B |
| IPO Year | N/A | 1987 |
| Metric | GMAB | COHR |
|---|---|---|
| Price | $33.84 | $197.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $40.00 | ★ $160.85 |
| AVG Volume (30 Days) | 2.0M | ★ 3.8M |
| Earning Date | 02-11-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.41 | N/A |
| EPS | ★ 25.10 | 0.76 |
| Revenue | $3,845,670,022.00 | ★ $6,043,358,000.00 |
| Revenue This Year | $24.85 | $17.43 |
| Revenue Next Year | $16.51 | $13.88 |
| P/E Ratio | ★ $13.05 | $258.78 |
| Revenue Growth | ★ 29.57 | 20.80 |
| 52 Week Low | $17.24 | $45.58 |
| 52 Week High | $35.43 | $213.30 |
| Indicator | GMAB | COHR |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 56.77 |
| Support Level | $30.88 | $186.03 |
| Resistance Level | $35.43 | $213.30 |
| Average True Range (ATR) | 1.01 | 14.21 |
| MACD | -0.09 | 0.34 |
| Stochastic Oscillator | 64.95 | 63.88 |
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.